Novel small molecule agonist improves behavior deficits and synaptic plasticity in a model of Alzheimer’s disease
Raj Amin, Ian Steinke, Fajar Wibowo, Sieun Yoo, Vishnu Suppiramaniam, Meenakshi Singh, Robert Rusty Arnold · 2025
Read Novel small molecule agonist improves behavior deficits and synaptic plasticity in a model of Alzheimer’s disease by Raj Amin, Ian Steinke, Fajar Wibowo, Sieun Yoo, Vishnu Suppiramaniam, Meenakshi Singh, Robert Rusty Arnold (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11714123.txt.
Description
Raj Amin and co-authors tested a new brain receptor drug in Alzheimer's mice in two thousand twenty-five. Cholesterol handling in brain goes wrong in the disease. A nuclear receptor steers that handling. Older drugs for it harmed liver and blood counts. Their molecule was designed on a computer first. It favors the safer receptor subtype strongly.
Partial activity at partner receptors adds balance. Treated mice behaved better in memory tasks. Synaptic plasticity, the learning substrate, improved too. The design aims to dodge past side effects. Human safety remains to be proven, of course. The study nominates a cleaner drug candidate. Cholesterol pathways stay in Alzheimer's crosshairs.
Catalog record
| CREATOR | Raj Amin, Ian Steinke, Fajar Wibowo, Sieun Yoo, Vishnu Suppiramaniam, Meenakshi Singh, Robert Rusty Arnold |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |